An independent evaluation of ASHM’s HBV s100 Prescriber Program was conducted in 2018, covering the period 1 Jul 2015 – 31 December 2017. The evaluation was mixed-methods, comprising interviews with GP prescribers, specialists, government representatives, program partners and consumers (n=30), a survey of GP prescribers (n=135), as well as a review of program data and analysis of population-level data. A summary of the results of the evaluation is presented here.